Companies /Healthcare

HCA Healthcare Inc

NYSE: HCA Medical Care Facilities
$451.06
▲ $6.05 (+1.36%) today
Markets closed · 6:02pm ET

24/7 Wall St. View

HCA at a Glance

Valuation
Market cap
$98.7B
P/E ratio
14.9
Dividend yield
0.68%
Profitability
Revenue (TTM)
$78.0B
Profit margin
8.8%
EPS (TTM)
$29.83
Price
52-week range
$353 – $554
24/7 target
$521.85
Street target
$454.23
Earnings
Next report
Oct 27, 2026

Headquartered in Nashville, TN Fiscal year ends December NYSE: HCA hcahealthcare.com

About HCA Healthcare

HCA Healthcare, Inc. is one of the largest for-profit hospital operators in the United States. As of June 30, 2026, the company operated 190 hospitals and approximately 2,600 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers, and physician clinics across 19 U.S. states and the United Kingdom. The company generates revenue primarily from inpatient and outpatient hospital services, with reimbursement from government payers (Medicare, Medicaid, and supplemental payment programs), commercial insurers, and self-pay patients. HCA's scale allows it to invest heavily in capital expenditures, technology, and resiliency initiatives while returning capital to shareholders through dividends and substantial share repurchase programs. The company's results are significantly influenced by payer mix dynamics, including enrollment trends on health insurance exchanges, Medicaid supplemental payment program approvals at the state level, and broader healthcare policy developments. Updated

HCA Coverage

12:40pm ET
Investing

5 Best IPOs of 2011

Here are the best IPOs of 2011, ranked according to how well the stocks have performed since they went public.

Trey Thoelcke

Frequently Asked Questions

What does HCA Healthcare do?

HCA Healthcare, Inc. is one of the largest for-profit hospital operators in the United States.

What is the HCA stock price target?

24/7 Wall St.'s 12-month price target for HCA is $521.85, rated Buy. The Wall Street consensus target is $454.23. HCA price prediction →